1) 日本臨床腫瘍学会 (編) : 発熱性好中球減少症 (FN) 診療ガイドライン改訂第2版. 南江堂, 東京, 2017
2) JAID/JSC感染症治療ガイド・ガイドライン作成委員会 (編) : JAID/JSC感染症治療ガイドライン. 日本感染症学会・日本化学療法学会, 東京, 2014
3) Smith TJ, Bohlke K, Lyman GH, et al : Recommendations for the Use of WBC Growth Factors : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33 : 3199─3212, 2015
4) Crawford J, Becker PS, Armitage JO, et al : Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15 : 1520─1541, 2017
5) Schiffer CA, Anderson KC, Bennett CL, et al : Platelet transfusion for patients with cancer : clinical practice guideline of the American Society of Clinical Oncology. J Clin Oncol 19 : 1519─1538, 2001
6) 日本癌治療学会 : 制吐薬適正使用ガイドライン2015年10月 (第2版). 金原出版, 東京, 2015
7) Benson AB 3rd, Ajani JA, Catalano RB, et al : Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22 : 2918─2926, 2004
8) Dimopoulou I, Bamias A, Lyberopoulos P, et al : Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 17 : 372─379, 2006
9) Kubo K, Azuma A, Kanazawa M, et al : Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respiratory investigation 51 : 260─277, 2013
10) Lenz HJ : Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12 : 601─609, 2007
11) Ries F and Klastersky J : Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8 : 368─379, 1986
12) Goolsby T and Lombardo FA : Extravasation of chemotherapeutic agents : prevention and treatment. Semin Oncol 33 : 139─143, 2006